Minimum Commitment: $1,000 | Deadline is Monday, May 18th
You are seeing this deal because you are a member of Vector3 Syndicate.
AI clinical decision platform that answers physician queries using verified, peer-reviewed medical literature with transparent citations
Secondary | Backed by All Top-20 U.S. Pharma Companies
Hi {{first_name}},
Clinical AI has struggled to earn physician trust — not because the technology is weak, but because healthcare demands auditable answers, not confident guesses. The platforms that have succeeded are those that built directly inside clinical workflow, at the moment decisions get made. That category is now scaling: combined pharma digital spend directed at physicians is estimated between $13B and $38B in the near term, with a longer-term expansion path toward enterprise hospital software and clinical trial infrastructure that extends the addressable market further.
OpenEvidence is the evidence-based AI platform built exclusively for clinicians: physicians ask clinical questions and receive responses grounded entirely in peer-reviewed literature, each answer linked to a verifiable source. The platform reached 484,000 monthly active users by the end of 2025 — approximately 37% of all U.S. clinicians — and is now present in roughly 1 in 10 U.S. patient visits. Unlike physician-facing ad networks, OpenEvidence captures pharmaceutical spend at the precise moment a prescribing decision forms, with monetized queries billed at $9.00 for new contracts, up from a $3.36 average in 2025. With only ~20% of total query volume currently monetized, the company carries a substantial revenue expansion path without needing to grow its user base.
This is a secondary transaction at a ~$14B valuation, reflecting a 2.3x markup from prior secondary transactions that cleared around $6B. The company reached $169M ARR within 15 months of its first commercial sale, with all top-20 U.S. pharma companies now paying customers across 86 total accounts. Vector3 Syndicate has secured access to this opportunity ahead of further secondary pricing; minimum commitment is $1,000.
OpenEvidence was founded in 2022 by Daniel Nadler and Zachary Ziegler. Nadler previously founded Kensho, the financial AI company acquired by S&P Global for $550M, bringing a proven track record of building and exiting category-defining data infrastructure businesses. Ziegler, CTO, holds a Harvard PhD in AI and leads the technical architecture underlying the platform's evidence retrieval and verification systems. The pairing of a serial infrastructure founder with a deep AI specialist maps directly to what the product required: credibility at the clinical layer built fast.
Access our Syndication Deal Room below to learn more. The deadline for committing to this opportunity is Monday, May 18th at 5 pm CST.
